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Abstract: Despite being a leading cause of death in the West, the pathophysiology of abdominal aortic aneurysms (AAA) 
is still incompletely understood. Pharmacotherapy to reduce the growth of small AAAs is limited and techniques for  
repairing aneurysms continue to evolve. Experimental models play a key role in AAA research, as they allow a detailed 
evaluation of the pathogenesis of disease progression. This review focuses on in vivo experimental models, which have 
improved our understanding of the potential mechanisms of AAA development and contributed to the advancement of 
new treatments. 
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INTRODUCTION 
  Abdominal aortic aneurysm (AAA) has a prevalence of 
5%, accounting for over 11,000 hospital admissions and 
10,000 deaths per year in the UK [1]. It affects primarily 
older males where ruptured AAA results in approximately 
2% of total mortality in men over 65 years of age [2]. Other 
risk factors include family history, hypertension, hypercho-
lesterolaemia, atherosclerosis and cigarette-smoking [3, 4]. 
  Whilst most AAAs are asymptomatic, expanding aneu-
rysms can cause pressure symptoms and more significant 
symptoms include distal embolisation and rupture. Patients 
with free intraperitoneal rupture rarely reach hospital alive 
and for those who have surgery, perioperative mortality is 
approximately 50% [1]. 
  The mainstay of AAA management is therefore elective 
repair prior to rupture. Based on results of the MRC small 
aneurysm trial where 30-day mortality from elective surgery 
was 5.8%, AAAs of less than 5.5cm diameter are managed 
conservatively whilst those above this size are considered for 
repair [5]. Methods of repair consist predominantly of open 
or endovascular repair. There is evidence that for those who 
are suitable for endovascular repair, this procedure is associ-
ated with reduced morbidity and mortality [6]. 
  For patients with small AAAs (<5.5cm), aggressive risk 
factor management is required to reduce cardiovascular 
morbidity and mortality. Pharmacotherapy to reduce AAA 
growth rate remains limited, although statins have been 
shown to be effective [7]. 
  Despite the clinical importance of AAAs, the aetiology 
and pathogenesis involved remain unclear. Histological 
analyses of aneurysm wall sampled at surgery demonstrate a 
loss of medial elastin and smooth muscle with excessive 
deposition of adventitial collagen and arterial wall thickening 
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[8]. However, these observations represent late changes that 
occur and do not necessarily reflect processes involved in 
disease development. 
 In  vitro models have been used in AAA research both to 
investigate pathophysiology and to assess new technologies. 
Thompson et al. described a model of aortic organ culture 
where 1cm
2 segments of porcine thoracic aorta were pre-
incubated in pancreatic elastase for 24 hours prior to stan-
dard organ culture conditions for 14 days [9, 10]. Aortic ex-
tracellular matrix degradation and increases in matrix metal-
loproteinases (MMP) expression were found. When autoge-
nous leucocytes were added to the culture after 48 hours of 
elastase incubation, an inflammatory infiltrate developed and 
enhanced the matrix degradation that occurred. Further 
modifications of this model included culturing under laminar 
shear stress or static conditions. Whilst this was a useful 
model, the isolated aortic segments could only be maintained 
in culture for a limited period and the model may not reflect 
events that occur in vivo. For the investigation of novel tech-
niques, in vitro models of varying sophistication have been 
described, using either synthetic materials or a combination 
of synthetic and biological materials [11-13]. These play an 
important role in “proof of concept studies” but require fur-
ther validation prior to clinical use. 
  This underscores the importance of in vivo animal mod-
els; enabling researchers to test hypotheses relating to AAA 
pathogenesis and to investigate potential pharmacotherapy. 
They have also played a key role in the development of new 
interventions for the treatment of AAAs with the aim of re-
ducing peri-operative morbidity and mortality. 
  This review will outline some of the animal models that 
have been used, focusing on the contributions they have 
made to our understanding and management of AAAs. 
ANIMAL MODELS 
  Animal models can be broadly classified into three cate-
gories: genetically predisposed animal models, chemical 
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Genetically Predisposed Animal Models 
 Early  in vivo studies of AAA relied on animals with sus-
ceptibility to atherosclerosis and aneurysm formation. The 
Broad Breasted Bronze and American Mammoth Bronze 
breeds of turkeys were noted to develop rupture of dissecting 
aneurysms [14]. Manipulation or supplementation of their 
feeds with various compounds altered the risk of rupture. For 
example, feeding these animals beta-aminoproprionitrile, the 
active agent in sweet pea meal, increased the risk of rupture 
[15] and the effects were further exacerbated by diethylstil-
bestrol, monoamine oxidase inhibitors, and hydralazine [16-
18]. The latter was found not to act via its haemodynamic 
effects but by accumulating in the aortic media and reacting 
with collagen groups. In contrast, propranolol and reserpine 
decreased the risk of aortic rupture [17, 19]. Whilst both 
these agents altered haemodynamics, propanolol also in-
creased elastin cross-linking [15, 18]. These early studies 
established the involvement of haemodynamic factors and 
connective tissue changes in the development and rupture of 
aortic aneurysms. 
 The  blotchy mouse was also found to develop spontaneous 
anuerysms [20]. These mice have a genetic abnormality   
on the X chromosome which results in defective collagen 
and elastin cross-linking. They develop abnormalities in   
connective tissue, skin colour and neurological function, due 
to an underlying defect in copper metabolism [21]. They also 
develop saccular and fusiform aneurysms throughout the 
aorta, but predominantly in the thoracic aorta [20]. Propra-
nolol delayed aneurysm formation probably by a combina-
tion of haemodynamic effects and increased elastin and col-
lagen cross-linking [22, 23], whilst hydrocortisone induced 
aortic rupture in these mice [24]. Based on these findings, 
altered copper metabolism was proposed to contribute to 
aneurysm development in humans, however, no change in 
copper levels in aortic tissue from patients with AAA have 
been reported [25, 26]. 
  Whilst these animals were useful models and increased 
our early understanding of the pathophysiology of aneu-
rysms, genetically altered mice have been more valuable for 
the study of specific molecular pathways involved. For ex-
ample, mice with a genetically engineered deficiency in lysyl 
oxidase (Lox), which is important in the crosslinkage of 
elastin and collagen, die in the perinatal period of ruptured 
thoracic aortic aneurysms [27]. Apolipoprotein E (ApoE) 
and low-density lipoprotein (LDL) receptor knockout mice 
fed on high-fat diets develop suprarenal aortic aneurysms 
[28]. Tsukuba hypertensive mice produced by cross-mating 
transgenic mice carrying either the human renin or human 
angiotensinogen genes [29] developed chronic hypertension 
and died of ruptured aortic aneurysms when fed drinking 
water containing 1% sodium chloride. The aneurysms were 
found to be predominantly located at the aortic arch or the 
juxtarenal segment of the abdominal aorta [30]. Mice with 
MMP-3 or tissue inhibitor of MMP (TIMP)-1 deficiencies 
develop aneurysms in both thoracic and abdominal aortas 
[31, 32]. Some of these mice however are not suitable ex-
perimental models since they died early of ruptured aneu-
rysms or developed aneurysms at atypical locations. Others 
have been successfully used in chemical models as described 
below. 
Chemical Models 
  Models where aneurysms have been induced by the ap-
plication of chemical agents have been useful in elucidating 
the aetiology and molecular mechanisms of aneurysm forma-
tion. They are also useful tools for testing potential pharma-
cotherapy in AAA management.  
  Extraluminal application of calcium chloride (CaCl2) 
solution to arteries results in aneurysm formation. This was 
first described in a study using rabbit common carotid artery, 
where progressive focal dilatation of the artery occurred, 
with loss of endothelial cells, disruption of the internal elas-
tic lamina, intimal hyperplasia and inflammatory infiltration 
of the media [33]. This method was then applied to rabbit 
aortas, where 2cm of proximal infrarenal aorta was dissected 
out and CaCl2 applied with a cotton wool tip for 15 minutes 
[34]. 0.25ml/L CaCl2  was found to cause medial damage 
with vascular remodelling, reduction in insoluble collagen 
and increased gelatinases activity, leading to aneurysm for-
mation. Inflammation induced by thioglycollate together 
with diet-induced hypercholesterolaemia led to rapid aneu-
rysmal dilatation. A murine model was also successfully 
created using a similar technique. Aortas increased by 64% 
in diameter 2 weeks after treatment and by 110% 3 weeks 
after treatment [35]. Aneurysms formed demonstrated dis-
ruption of the media elastic network and activation of the 
inflammatory response as seen in human AAAs, suggesting 
that this is a clinically useful model. A murine model offers 
the advantage of working with mice, which are low cost, 
easy to handle, have a short life cycle as well as a well-
studied genome suitable for genetic manipulation. 
  Using this model in genetically altered mice, the role of 
MMPs in AAA formation has been established: MMP2 -/- 
and MMP9 -/- knockout mice did not form aneurysms [36], 
whilst MMP12 -/- mice showed attenuated aortic dilatation 
compared to wild-types following CaCl2-mediated injury 
[37]. As the MMPs are tightly regulated by the TIMPs, their 
role has also been studied. Surprisingly, in mice deficient in 
TIMP-2, CaCl2-mediated injury resulted in significantly 
smaller aneurysms than wild-types at 6 weeks [38], suggest-
ing that there is a complex interaction between the MMPs 
and TIMPs. The hypothesis that chemokines are involved in 
neutrophil infiltration of the aortic wall in aneurysm devel-
opment was tested using mice with genetic deletions of the 
chemokine receptors CCR2, CCR5 and CXCR3. Six weeks 
after CaCl2-mediated injury, aneurysm formation was at-
tenuated in CCR2 -/- mice with reduced inflammatory infil-
tration whilst CCR5 and CXCR3 deletion conferred no pro-
tection against aneurysm formation [39]. 
  Agents that may reduce aneurysm formation or growth 
have been studied using this model. For example, daily oral 
doses of the anti-inflammatory agent indomethacin following 
CaCl2 application resulted in less disruption of the elastic 
layers within the aortic wall and reduced aortic dilatation 
three weeks after surgery in rats [40]. The effect of pentagal-
loyl glucose (PGG), a polyphenolic tannin, on aneurysm 
formation and growth in rats, has also been explored [41]. 
Pre-treating rat aortas with PGG prior to CaCl2 application 
inhibited aneurysm formation whilst applying PGG to aneu-
rysms formed 28 days after CaCl2 injury prevented further 
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preventing elastin degradation despite high levels of MMPs 
[41].  
  The elastase-induced model is another important model, 
first described by Anidjar et al. [42]. The procedure involved 
dissecting out the rat abdominal aorta followed by insertion 
of a catheter via the femoral artery into the infrarenal aorta. 
The aorta was then clamped at the level of the left renal vein 
and ligated around the catheter 1cm distally. This segment of 
isolated aorta was then perfused with 2ml of fluid at 1ml/ 
hour. After 2 hours, the aorta was unclamped, the suture and 
catheter removed and the femoral artery ligated. Perfusion of 
hog pancreatic elastase resulted in destruction of the media 
elastin network with immediate aortic dilatation followed by 
aneurysm formation over 2-5 days. These findings supported 
the hypothesis that elastolytic activity within the media plays 
a role in aneurysm formation and provided a useful repro-
ducible model for further investigations. 
  Using this model, documented risk factors for AAA were 
investigated. The role of hypertension in AAA growth was 
examined by Gadowski et al. by inducing aneurysms in 
normotensive Wistar-Kyoto rats (WKY) and genetically hy-
pertensive Wistar-Kyoto rats (WKHT) [43]. Initially, aortic 
diameters were the same but by day 7, WKHT rats had larger 
aneurysms than normotensive rats (mean diameter 2.52 vs. 
2.31mm) and at day 14, the difference was even greater 
(3.45 vs. 2.36mm). Growth rates were also significantly in-
creased in WKHT rats and showed strong positive correla-
tion to systolic blood pressure. This study confirmed the role 
of hypertension in AAA expansion. 
  In order to study the role of gender, Upchurch’s group 
investigated the effect of gonadal hormone manipulation on 
aneurysm diameter in rats 14 days following elastase-
infusion [44]. They found that experimental aneurysm di-
ameter decreased in male rats treated with exogenous oestro-
gen, decreased in orchidectomised males, increased in surgi-
cally castrated males given hormone replacement but de-
creased in castrated females on hormone replacement ther-
apy. Altered macrophage numbers in the aortic walls of these 
animals were found, suggesting that gonadal hormones dif-
ferentially regulated AAA growth by altering macrophage 
infiltration. 
  Epidemiological studies have shown that smokers have a 
3- to 6-fold increase in AAA-related death [45]. Bergoeing et 
al. demonstrated that this was likely to be a causal relation-
ship by exposing mice to cigarette smoke in special cages 2 
weeks before inducing aortic aneurysms using the elastase-
induction model [46]. Exposure to cigarette smoke was con-
tinued for 2 weeks until the end of the experiment. In mice 
not exposed to cigarette smoke, 0.16 U/ml of pancreatic elas-
tase resulted in aneurysm formation in 100% whilst a lower 
dose of 0.07 U/ml only caused aneurysms in 63% of mice. In 
contrast, when exposed to cigarette smoke, 85% of mice 
developed aneurysms following 0.07 U/ml of elastase and 
the aneurysms were 60% larger in size. Cigarette smoke in-
creased aortic elastic degradation in these aneurysms without 
affecting aortic MMP levels.  
  As with the CaCl2 model, the use of this model in geneti-
cally modified mice has elucidated some of the key molecu-
lar mechanisms involved in aneurysm formation. Aneurysm 
induction by elastase infusion was inhibited in MMP9 -/- and 
mice deficient in both MMP9 and MMP12. In contrast, 
MMP12 -/- mice were not resistant to aneurysm formation. 
Transplantation of bone marrow cells from wild-type mice 
into irradiated MMP9 -/- mice resulted in aneurysm forma-
tion. The study confirmed the importance of MMP9 in aneu-
rysm formation in this model and also suggested that infil-
trating inflammatory cells were an important source of 
MMP9 [47]. The role of TIMP-1 was also demonstrated us-
ing this model: TIMP1 -/- mice developed larger post-
infusion aortic diameters and significantly larger aneurysms 
at day 14 compared to wild-types [48]. 
  Interesting findings regarding the role of the nitric oxide 
(NO) pathway have also been demonstrated using the elas-
tase infusion model. In wild-type animals, nitric oxide syn-
thase (NOS) 1 and 3 expression in aneurysms was reduced, 
whilst NOS 2 expression was increased, localised to infiltrat-
ing inflammatory cells. This suggested that NOS 2 may be 
involved in the inflammatory component of aneurysm 
development. However, in male NOS2 -/- mice the incidence 
and size of aneurysms formed were unaffected whilst in 
female NOS2 -/- mice, increased incidence and size of 
aneurysms occurred. This latter effect was prevented by 
previous oophrectomy, suggesting an interaction between 
NOS2 and gonadal hormones [49]. 
  The role of the proinflammatory cytokine interleukin-6 
(IL-6) has also been investigated using this model. In mice 
with targeted deletion of IL-6, suppression of aneurysm   
formation occurs with reduced inflammatory response [50]. 
  Important information on potential pharmacotherapy for 
AAA has been gained from the elastase infusion model. In-
domethacin given daily for 7 days following elastase infu-
sion in rats was again found to inhibit aneurysm formation 
[51]. The effect of statins independent of their cholesterol-
lowering properties was studied using this model in rats, 
since statins do not lower cholesterol in these animals. Sim-
vastatin given by daily gastric gavage starting the day before 
surgery led to reduced aneurysm size 7 days following elas-
tase infusion with downregulation of genes involved in in-
flammation, extracellular matrix remodelling and oxidative 
stress response [52]. Atorvastatin was also found to signifi-
cantly reduce aneurysm size at 4 weeks, with evidence of 
reduced macrophage recruitment, MMP-12 expression and 
increased aortic wall collagen and elastin content [53]. Pro-
panolol was found to reduce the size of elastase-induced 
aneurysms in hypertensive rats but had no effect on nor-
motensive rats, suggesting that its effect was predominantly 
via its blood pressure lowering properties [54]. In contrast, 
the calcium channel antagonist nifedipine was found to re-
duce aneurysm size progression without affecting blood 
pressure or heart rate following elastase infusion in rats [55]. 
The angiotensin-converting enzyme (ACE) inhibitors capto-
pril, lisinopril and enalopril all reduced aneurysm size inde-
pendent of haemodynamic effects in rats 14 days after elas-
tase infusion with reduced medial elastin degradation and 
inflammation. In addition, angiotensin (Ang) II (AT1) recep-
tor antagonist losarten did not affect aneurysm size com-
pared to control treatment [56]. However, in another study, 
an alternative AT1 receptor antagonist valsartan, given fol-
lowing elastase infusion in rats significantly reduced aneu-
rysm development without affecting blood pressure [57]. 
Given the likely involvement of MMPs in aneurysm patho-224    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Janice C. Tsui 
genesis, the effects of MMP-inhibiting tetracylines have 
been evaluated. Doxycycline was found to inhibit aorta dila-
tation in a dose- dependent manner, by reducing medial 
elastin degradation [58]. 
  Innovative strategies have also been investigated using 
this model. For example, Nakashima et al. used decoy 
oligodeoxynucleotides to inhibit the transcription factors 
NFB and ets in rat and rabbit elastase infusion models [59, 
60], whilst Miyama et al. applied biodegradable gelatin 
hydrogel sponge incorporating basic fibroblast growth factor 
over the aortas of rats [61]. Both these strategies inhibited 
AAA progression.  
  Problems with and modifications of these techniques 
have been described by investigators. Carsten et al. were 
concerned that the sizes of the aneurysms produced by Anid-
jar’s technique were inconsistent and may be related to 
variations in elastase preparations. They also found that long 
infusion periods were required, which were associated with 
higher rates of complications such as lower limb ischaemia 
[62]. Others found that aneurysm formation rates may be low 
following CaCl2 injury [41]. Recently, Tanaka et al. de-
scribed a rat model which combined a 20-minute infusion of 
elastase with extraluminal application of CaCl2 (Fig. 1) [63]. 
In a series using 71 rats, they had a high success rate of AAA 
formation of 92.7% with no complications and aneurysms 
formed showed inflammatory responses, elastolytic activities 
and MMP expression. However, saccular aneurysms were 
predominantly formed and like the other chemical models, 
the aneurysms were not associated with atherosclerosis and 
intraluminal thrombosis as seen in human AAAs.  
 
Fig. (1). Schematic drawing of experimental AAA model using a 
combination of intraluminal elastase infusion and extraluminal 
calcium chloride exposure [63]. 
  Whilst rodents provide valuable experimental models, 
their small size renders them challenging to operate on. A 
fusiform rabbit carotid artery model created by infusing elas-
tase into a 2cm segment of the common carotid artery has 
been described [64]. This model offered accessibility to the 
aneurysm; however its size was still not suitable for the pur-
pose of testing new techniques of aneurysm exclusion. The 
use of the elastase-perfusion technique in larger animals has 
been less successful: canine models have generally not been 
reproducible despite various protocols of elastase or elastase-
collagenase infusion [65]. A study using Yucatán miniature 
swine did not create any aneurysms despite destruction of 
media elastic network following elastase infusion [66]. Re-
cently, a porcine model has been successfully created using a 
combination of elastase and collagenase infusion and me-
chanical dilation [67]. This will be discussed below together 
with the physical models.  
 Manning  et al. [68] used systemic Ang II infusion in their 
model. Here, Ang II was infused by subcutaneous osmotic 
pumps into ApoE -/- or LDL receptor -/- mice. This resulted 
in accelerated atherosclerosis and development of aneurysms 
in the suprarenal portion of the aorta, which demonstrated 
many of the characteristics of human disease, such as medial 
degeneration and remodelling, inflammation and thrombosis. 
Male mice were more susceptible to AAA development than 
females. Microarray gene analyses of aortic aneurysms con-
firmed that upregulation of inflammatory and extracellular 
matrix remodelling pathways occur, as seen in human AAAs 
[69]. The effects of pharmacological, surgical and genetic 
manipulation on AAA development in this model have been 
investigated [70]. Hydralazine lowered systolic blood pres-
sure but had no effect on aneurysm formation in Ang II in-
fused ApoE-/- mice showing that aneurysm formation in this 
model was independent of blood pressure [71]. 17 beta-
oestradiol pre-treatment reduced the incidence and severity 
of aneurysms in male ApoE -/- mice infused with Ang II 
[72], whilst dihydrotestosterone increased aneurysm inci-
dence in castrated male and female Ang II infused ApoE -/- 
mice, which was associated with increased AT1 receptor 
mRNA expression in aortas [73]. The effect of androgens on 
aneurysm development was supported by experiments show-
ing reduced aneurysm incidence and severity in orchidec-
tomised male ApoE -/- mice infused with Ang II [74]. Vari-
ous agents were used to investigate further the role of the 
renin-angiotensin system in this model: co-infusion of the 
AT1 receptor antagonist losarten with Ang II in ApoE -/- 
mice completely inhibited aneurysm formation whilst co-
infusion with the AT2 receptor antagonist PD123319 in-
creased the incidence and severity of aneurysms [75]; cande-
sarten, another AT1 antagonist and lisinopril, an ACE inhibi-
tor, given after Ang II infusion in ApoE -/- mice attenuated 
expansion of aortic aneurysms [76]; pre-treatment with the 
aldosterone receptor antagonist spironolactone had no effect 
on aneurysm formation [77]. Doxycycline was found to re-
duce the incidence and severity of aneurysm formation in 
Ang II infused LDL receptor -/- mice [78]; vitamin E attenu-
ated aneurysm formation and size of aneurysms formed in 
Ang II treated ApoE-/- mice [79]; simvastatin reduced the 
incidence and extent of aneurysm formation with reduced 
remodelling and inflammatory response seen in aortic walls 
[80]; and rosiglitazone reduced the maximum size of the 
aneurysms formed and inhibited rupture when given before 
or after Ang II infusion in ApoE-/- mice [81].  
  Combining this model with genetically altered animals 
has also yielded interesting results. For example, the role of 
urokinase plasminogen activator (UPA) in aneurysm forma-
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both ApoE and UPA where the incidence of aneurysm for-
mation was reduced compared to in ApoE -/- mice [82]. Fur-
thermore, local overexpression of the key inhibitor of UPA, 
plasminogen activator inhibitor-1 (PAI-1) in ApoE -/- mice 
using intra-adventitial injections of recombinant adenovirus 
expressing the human PAI-1 gene prior to Ang II infusion 
inhibited aneurysm formation, whilst administration of the 
gene 2 weeks after Ang II infusion prevented expansion of 
small aneurysms [83]. As increased cyclooxygenase (COX)- 
2 expression has been found in human AAAs, COX-2 defi-
cient mice were also studied and found to have significantly 
reduced incidence of aneurysm formation, associated with 
reduced inflammatory cell infiltration of the aorta following 
Ang II infusion compared to wild-types [84]. These studies 
demonstrate the value of combining genetically altered ani-
mals with pharmacological models of AAA formation.  
Physical Models 
  A range of physical techniques have been used to create 
aneurysms in animals for investigation. However, since   
the pathology of these models does not reflect that of true 
aneurysms in humans, their use is mainly limited to the   
assessment of new interventions for AAA repair. With the 
advent of endovascular aneurysm repair (EVAR) techniques  
described by Parodi in 1991[85], these models have been 
valuable in the development of stent grafts, resulting in   
improved designs, delivery systems and understanding of 
specific complications of endovascular repair.  
  Crude methods of inducing aortic aneurysms included 
traumatising the vessel wall with intramural injections of 
chemicals such as acetrizoate [86] or physical damage using 
cryogenic probes, carbon dioxide lasers or simply surgically 
resecting the media and adventitia of the aorta [87-89]. 
These methods generally produced aneurysms of unpredict-
able size, growth rate and rupture risk and more often re-
sulted in saccular aneurysms or even pseudoaneurysms.  
  Synthetic aneurysm models included the replacement of a 
segment of aorta with interposition grafts made of synthetic 
or autologous materials. These produced aneurysms of more 
consistent shape and size but do not preserve lumbar and 
mesenteric collateral circulation to the sac. Parodi and Pal-
maz’s group replaced a segment of infrarenal aorta with a 
fusiform synthetic aneurysm made of woven Dacron in dogs 
to evaluate an early stent graft made of Dacron and balloon-
expandable stents. This early study showed that the tech-
nique was feasible and identified problems related to device 
introduction, deployment and fixation [90]. 
 Whitbread  et al. created a model by interpositioning a 
fusiform segment of glutaraldehyde-tanned bovine internal 
jugular vein into the infrarenal aortas of large white pigs 
[91]. The resulting aneurysm had an aorta to aneurysm di-
ameter ratio of 1:2. These aneurysms were stented 2 weeks 
later using plain 48-wire Wallstents (Schneider Stent, Inc., 
USA) via the left common carotid artery. Pigs were followed 
up for 6 weeks and assessed with ultrasound, angiography, 
pressure measurements and finally sacrificed for histology. 
Three out of 6 aneurysms were successfully excluded imme-
diately whilst the remaining 3 were partially treated with 
reduction in aneurysm size and sac pressure. In 2 cases, the 
stent was inadvertently deployed over the renal arteries but 
no flow disturbance was found on follow-up. The authors 
suggested that stents could therefore be designed with a cen-
tral covered portion flanked by uncovered portions for fixa-
tion. This study not only presented a new AAA model and 
confirmed the potential of endovascular techniques but also 
contributed to advancement in stent graft design. 
  The anterior patch model is another successful physical 
model, where following a longitudinal aortotomy, an ellipti-
cal patch of either autologous or synthetic material was used 
to close the aortotomy. For example, Criado et al. created 
infrarenal aortic aneurysms by suturing full thickness jejunal 
patches to longitudinal anterior aortotomies in dogs to test 
the longer term efficacy of endovascular aortic repair [92]. 
Six out of 7 untreated aneurysms ruptured within 6 days. In 
11 dogs, the aneurysm was stented using an 8mm Dacron 
graft introduced via the femoral artery. Dogs were followed 
up with pressure measurements, angiography and histology 
when sacrificed at 3 and 6 months. Three aneurysms were 
not excluded successfully and ruptured within 4 days. Two 
dogs from the earlier part of the study became paraplegic due 
to stent kinking and thrombosis. The remaining aneurysms 
were successfully excluded with incorporation of graft mate-
rial into the surrounding tissue, which was evident at 3 
months with no evidence of graft migration.  
 Eton  et al. also used an autologous anterior patch model 
in mongrel dogs to assess a specific stent graft design and 
delivery system [93]. Here, an iliac vein patch was used to 
form fuisform infrarenal aneurysms. This model was more 
realistic as the lumbar and mesenteric branches were pre-
served, allowing the effect of patent side-branches on subse-
quent aneurysm exclusion and size to be studied. Twenty 
three dogs with aneurysms were treated with Dacron stent 
grafts and followed up for 6 to 12 months. At 12 months, 
there were no leaks or flow within the sac and no sac   
enlargement, confirming the feasibility of this technique   
despite the presence of patent side branches. 
  Whilst the benefits of EVAR include reduced 30-day 
mortality, better early health-related quality of life and im-
proved long-term aneurysm-related survival, EVAR is asso-
ciated with significantly increased secondary intervention 
rate [6, 94]. Advances in stent graft technology have reduced 
specific complications such as graft migration and thrombosis, 
but endoleaks remain causes of re-intervention. Endoleaks 
result in continued pressurisation of the aneurysm sac due to 
persistent flow outside the stent graft. They occur in up to 
26% of patients following EVAR [95] and may lead to aortic 
rupture [96]. Endoleaks due to incompetent seal at attach-
ment sites (type I) and between modular components (type 
III) result in incomplete exclusion of the aneurysm and   
require early intervention. These have been reduced with 
improved graft design and planning. Type IV endoleaks   
occur through porous graft material and are now rarely   
seen. Type II endoleaks result from flow into and out of the 
aneurysm sac from patent side-branches such as the inferior 
mesenteric or lumbar arteries (Fig. 2). Whilst it was recog-
nised that Type I and III endoleaks required urgent treatment 
to prevent aortic rupture, the clinical significance of type II 
endoleaks were less clear. 
  In order to study the significance of type II endoleaks, 
specific models were developed by some groups. Mousa   
et al. modified a prosthetic model in dogs by dilating   
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angioplasty balloon and incorporating intraluminal pressure 
transducers to monitor sac pressures [97]. At implantation, a 
segment of native aorta with 2 or more patent side branch 
vessels (lumbar +/- caudal mesenteric arteries) were reim-
planted onto the posterior aspect of the prosthetic aneurysm. 
Before endovascular exclusion with a PTFE-covered stent 
graft, pressures within the aneurysm sac closely matched 
systemic pressures. In models where no side branches were 
reimplanted, endovascular stenting resulted in significant 
reduction in sac pressures and no endoleak. In the presence 
of patent side branches, endovascular stenting resulted in a 
smaller fall in sac pressures and type II endoleaks were dem-
onstrated on angiography. The side branches remained patent 
on duplex and magnetic resonance angiography (MRA) 
throughout the study period of 90 days. This study demon-
strated that type II endoleaks resulted in significant sac pres-
sure and if persistent may be of clinical significance. How-
ever, the main limitation of this study was the use of rela-
tively nonexpansile prosthetic material to create aneurysms 
which were unlikely to simulate post-stenting aneurysms. 
 Diaz  et al. used a porcine anterior patch model where a 
4cm wide ellipse of Dacron was sutured to an infrarenal aor-
totomy [98]. Two lumbar arteries were preserved in all the 
animals and pressure transducers were implanted in the an-
eurysm wall. One week later, EVAR was performed with a 
custom-made stent graft. All the aneurysms were excluded 
with type II endoleaks via the lumbar arteries. Following 
EVAR, mean arterial pressure within the aneurysm sac de-
creased but pulse pressure persisted. A further week later, 
laparoscopic lumbar artery ligation was performed via a 
retroperitoneal approach which resulted in further reduction 
in mean arterial pressure and obliteration of pulse pressure 
within the aneurysm sac. Successful treatment of the type II 
endoleak was confirmed in all animals on CT scans and on 
histological analyses. This study showed that type II 
endoleaks were associated with persistent pulse pressure 
within the sac and that both sac pulse pressure measurements 
and CT scans were useful in identifying type II endoleaks. It 
also demonstrated that laparoscopic ligation of side branches 
was an effective way of treating type II endoleaks. The in 
 
Fig. (2). A: CT of a ruptured AAA in a 72 year old man with a large haematoma (yellow arrow) B: Intra-operative angiogram during urgent 
EVAR showing stent graft in position, excluding the AAA C: Post-EVAR CT showing stent graft in situ and type II endoleak. Contrast is 
seen within the sac outside of the stent graft (white arrow = stent graft, * = endoleak), arising from one of the lumbar arteries. The haema-
toma caused at the time of rupture is still present (yellow arrow). Experimental Models of Abdominal Aortic Aneurysms  The Open Cardiovascular Medicine Journal, 2010, Volume 4    227 
vivo porcine model created may provide a useful tool for the 
development and training of this technique. Unfortunately, 
the study period was short which did not allow for the natu-
ral history of type II endoleaks to be studied: it is now rec-
ognised that the majority of type II endoleaks resolve spon-
taneously within 6 to 12 months and do not require interven-
tion [95]. 
 More  recently,  Maynar  et al. described a version of the 
anterior patch model in swine where a 2-3mm wide segment 
of the aortic wall was resected following anterior aortotomy, 
and a double-layered oval peritoneal patch sutured to close 
the defect [99]. Aneurysm development in these animals was 
followed up with angiography as well as laparoscopic as-
sessment and laparoscopic ultrasound and finally histological 
analyses. The infrarenal aneurysms created increased in size 
up to 30 days post-operatively and 15 out of 27 aneurysms 
ruptured within 2 weeks. Laparoscopic assessment showed 
incorporation of patches into the aortic wall with almost 
complete endothelialization of the luminal wall. The authors 
argued that this model was more realistic than others due to 
its potential for aneurysmal growth and rupture. However, 
like other anterior patch models, the incorporation of bio-
logical material into the aortic wall limited its use in the 
study of tissue response to stent graft placement. Further-
more, whilst the side branches were preserved in this model, 
these arose from normal rather than aneurysmal aortic wall 
as seen in patients with AAAs. 
  In order to overcome some of these problems, a previ-
ously mentioned porcine model using a combination of me-
chanical aortic dilation and enzymatic connective tissue deg-
radation has been described by Hynecek [67]. A segment of 
infrarenal aortic was dissected out and gradually dilated with 
a non-compliant angioplasty balloon of 12-14mm diameter 
introduced proximal to the caudal mesenteric artery. This 
segment of aorta was then isolated with vascular clamps and 
infused with 50ml of a solution of collagenase and elastase 
under pressure for 20 minutes. The aortic lumen was irri-
gated to remove remaining solution prior to closing the arte-
riotomy. Aneurysm formation in 10 pigs was assessed with 
serial MRAs and histological evaluation when the animals 
were euthanised. Following mechanical dilation, there was a 
mean 62% increase aortic diameter and at 1, 3 and 6 weeks 
after surgery, aortic diameters had increased by 73, 83 and 
94% respectively. Histologically, there was early loss of en-
dothelial cells with gradual re-endothelialisation; mural neu-
trophil infiltration; loss of smooth muscle cell with limited 
repopulation; elastin disruption and persistent degradation 
and collagen disruption and degradation followed by deposi-
tion. These changes were similar to the degenerative changes 
that occur in human AAAs. Further work by this group has 
shown that gene expression in this model as demonstrated by 
gene arrays, replicated the patterns seen in human aneu-
rysms, predominantly with upregulation of extracellular ma-
trix remodelling and inflammatory genes and downregula-
tion of elastin [100]. This model therefore represents a large 
animal native aneurysm model which may be useful in the 
further development of stent graft technology, where the 
behaviour of novel components within abnormal aorta can be 
studied. In addition, the effect of endovascular intervention 
on AAA pathophysiology can also be investigated. The main 
drawback of this model is the absence of side branches since 
the lumbar arteries are ligated to ensure that the collagenase/ 
elastase solution does not enter the systemic circulation.  
  Another porcine model combined intraluminal infusion 
of porcine pancreatic elastase with the application of a   
plastic cuff below the level of the renal arteries in order to 
simulate turbulent flow [101]. The application of this model 
requires further evaluation. 
CONCLUSION 
 In  vivo models have been important in increasing our 
understanding of the pathophysiology of AAAs and continue 
to be valuable tools for the development of pharmacotherapy 
and new technologies for aneurysm repair. The models have 
limitations and appropriate choice of model according to the 
purpose of the study is important. Overall limitations include 
interspecies variation in anatomy, physiology and pharma-
codynamics. For example, the anatomy of some of the larger 
animal models may not be suitable for assessment of stent 
graft delivery systems for humans and variations in fibri-
nolytic systems may result in increased complications in 
some species [102]. Experimental models do not include the 
complex risk factors that patients are exposed to before and 
after aneurysm repair. The results from in vivo models may 
be hard to interpret particularly as results from different 
models may be conflicting and findings may not be applica-
ble to patients. Indeed, not all the potential pharmacological 
agents shown to be promising in animal models are effective 
clinically, where the main aims of pharmacotherapy are to 
reduce or prevent growth of small AAAs. In a recent sys-
tematic review and meta-analysis of pharmacotherapy for 
decreasing AAA expansion rate, statins were found to be 
effective whilst beta-blockers were not; ACE inhibitors, cal-
cium channel blockers, non-steroidal anti-inflammatory 
agents and doxycycline may be useful but require further 
evaluation [7].  
ABBREVIATIONS 
AAA =  Abdominal  aortic  aneurysm 
ACE =  Angiotensin  converting  enzyme 
Ang II  =  Angiotensin II 
Apo E  =  Apolipoprotein E 
AT1  =  Type 1 angiotensin II receptor 
AT2  =  Type 2 angiotensin II receptor 
Ca Cl2 = Calcium  chloride 
COX =  Cyclooxgenase 
EVAR  =  Endovascular aortic aneurysm repair 
LDL  =  Low density lipoprotein 
Lox =  Lysyl  oxidase 
MMP =  Matrix  metalloproteinase 
MRA =  Magnetic  reasonance  angiography 
NO =  Nitric  oxide 
NOS  =  Nitric oxide synthase 
PAI-1  =  Plasminogen activator inhibitor-1 
PPG =  Pentagalloyl  glucose 228    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Janice C. Tsui 
PTFE =  Polytetrafluroethylene 
TIMP  =  Tissue inhibitor of MMP 
UPA  =  Urokinase plasminogen activator 
WKHT =  Wistar  Kyoto  hypertensive 
WKY =  Wistar  Kyoto  rat 
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